Evidence map›Paper›PMID 32754913›Full record

ArticleJournal of neurochemistry2021

Detergent-insoluble inclusion constitutes the first pathology in PFN1 transgenic rats.

Guixiu Yuan, Shiquan Cui, Xuan Chen, Haochang Song, Cao Huang, Jianbin Tong, Zhentin Yuan, Lin Yu, Xinrui Xiong, Jihe Zhao and 6 more

Open access · greenAbstract read
In one paragraph

Article in Journal of neurochemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Profilin Isoforms in Health and Disease - All the Same but Different.Frontiers in cell and developmental biology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Guixiu YuanBurnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL, USA.
Shiquan CuiBurnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL, USA.
Xuan ChenBurnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL, USA.
Haochang SongBurnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL, USA.
Cao HuangDepartment of Pathology, Thomas Jefferson University, Philadelphia, PA, USA.
Jianbin TongBurnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL, USA.
Zhentin YuanBurnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL, USA.
Lin YuBurnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL, USA.
Xinrui XiongBurnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL, USA.
Jihe ZhaoBurnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL, USA.
Bo HuangDepartment of Pathology, Thomas Jefferson University, Philadelphia, PA, USA.
Qinxue WuDepartment of Pathology, Thomas Jefferson University, Philadelphia, PA, USA.
Yibo ZhouBurnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL, USA.
Gong ChenBurnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL, USA.
Hongxia ZhouBurnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL, USA.
Xu-Gang XiaBurnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL, USA.ORCID 0000-0002-1114-9666
University of Central Florida · USThomas Jefferson University · US

Funding

Gene Deregulation in Cortical DementiaRF1AG064822 · NIA · UNIVERSITY OF CENTRAL FLORIDA · PI XIA, XUGANG, ZHOU, HONGXIA · 2019 to 2019
$3.6M
Study on PFN1 Pathobiology Using Rat ModelsR01NS110455 · NINDS · UNIVERSITY OF CENTRAL FLORIDA · PI XIA, XUGANG, ZHOU, HONGXIA · 2019 to 2023
$3.0M
STUDY ON NEURODEGENERATION USING TDP-43 TRANSGENIC RATSR01NS073829 · NINDS · UNIVERSITY OF CENTRAL FLORIDA · PI ZHOU, HONGXIA · 2012 to 2020
$3.0M
TMEM230 and Neurodegeneration in Parkinson's DiseaseR01NS115039 · NINDS · FLORIDA INTERNATIONAL UNIVERSITY · PI XIA, XUGANG, ZHOU, HONGXIA · 2020 to 2024
$1.7M
Redesign Rat Model for ALS ResearchR01NS089701 · NINDS · UNIVERSITY OF CENTRAL FLORIDA · PI XIA, XUGANG, ZHOU, HONGXIA · 2014 to 2018
$1.7M
Study on hnRNPA1 Pathobiology in ALSR01NS095962 · NINDS · UNIVERSITY OF CENTRAL FLORIDA · PI XIA, XUGANG · 2016 to 2020
$1.6M
National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke NS07829National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke NS089701National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke NS095962National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke NS110455NIA NIH HHS RF1 AG064822NIH/National Institute on Aging AG064822NINDS NIH HHS R01 NS073829NINDS NIH HHS R01 NS089701NINDS NIH HHS R01 NS095962NINDS NIH HHS R01 NS110455NINDS NIH HHS R01 NS115039
6 · The paper itself

Abstract

Mutation of profilin 1 (PFN1) can cause amyotrophic lateral sclerosis (ALS). To assess how PFN1 mutation causes the disease, we created transgenic rats with human genomic DNA that harbors both the coding and the regulatory sequences of the human PFN1 gene. Selected transgenic lines expressed human PFN1 with or without the pathogenic mutation C71G at a moderate and a comparable level and in the similar pattern of spatial and temporal expression to rat endogenous PFN1. The artificial effects of arbitrary transgene expression commonly observed in cDNA transgenic animals were minimized in PFN1 transgenic rats. Expression of the mutant, but not the wild type, human PFN1 in rats recapitulated the cardinal features of ALS including the progressive loss of motor neurons and the subsequent denervation atrophy of skeletal muscles. Detergent-insoluble PFN1 inclusions were detected as the first pathology in otherwise asymptomatic transgenic rats expressing mutant human PFN1. The findings suggest that protein aggregation is involved in the neurodegeneration of ALS associated with PFN1 mutation. The resulting rat model is useful to mechanistic study on the ALS.

Indexed as

Amyotrophic Lateral SclerosisAnimalsInclusion BodiesMiceMotor NeuronsMuscle, SkeletalProfilinsRatsRats, Sprague-DawleyRats, TransgenicPFN1 protein, humanProfilinsaggregationALSneurodegenerationPFN1rat

Identifiers

PMID32754913
PMCPMC8994973
OpenAlexW3047018148

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.